News
13h
GlobalData on MSNMSD progresses once-monthly HIV PrEP into Phase IIIMSD unveiled the launch of the Phase III trials of MK-8527 at the International AIDS Society (IAS) 2025 conference.
Rahway: Merck, known as MSD outside of the United States and Canada, has announced the initiation of the EXPrESSIVE Phase 3 ...
Verastem Oncology releases primary results from phase 2 RAMP 201 trial of Avutometinib in combo with defactinib: Boston Tuesday, July 15, 2025, 09:00 Hrs [IST] Verastem Oncology, ...
Kester Capital-backed Evestia Clinical merges with US-based Atlantic Research Group (ARG) to create a leading independent global specialist CRO in fast-growing marketsThe merger delivers on Evestia ...
Esketamine monotherapy is linked to greater 28-day symptom reduction in treatment-resistant depression vs placebo, new research shows.
Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...
Ultragenyx's high burn rate, costly R&D, and recent setbacks increase dilution risk, impacting future profitability. Learn ...
9h
Clinical Trials Arena on MSNViiV’s HIV shot preferred, as activists spotlight funding crisis at IAS 2025ViiV's Cabenuva is administered every two months and was offered to HIV patients who achieved viral suppression from daily treatments.
17h
AllAfrica on MSNMomentum Builds For Long-Acting HIV Solutions As IAS 2025 Spotlights Scientific Progress, Funding Challenges And Leaders' Calls To ActionNew WHO guidelines endorse long-acting injectable lenacapavir for HIV prevention, Medicines Patent Pool expands licence for long-acting injectable cabotegravir for treatment, and Merck’s once-monthly ...
A recent phase 2b clinical trial in South Africa found that Bacille Calmette-Guérin (BCG) revaccination did not prevent ...
Cats with a severe coronavirus disease experienced an immune system boost after treatment with an MSC therapy, opening translational avenues for humans.
Dr. Vincent Ma discussed the most recent and notable treatment updates for patients with high-risk and advanced melanoma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results